About this trial
Psoriasis is a chronic inflammatory disease that affects the skin and joints in 2-3 % of people in the United States. This inflammation of the skin, joints, and blood vessels in patients with psoriasis has been measured by older PET Scan technology but with limitations. With the new EXPLORER PET scanner technology, the investigators are testing to see if the EXPLORER is better than previous PET scanners and improve our ability to assess inflammation in patients.
Also, it is known that the typical Western Diet - high in saturated fats, added sugars, and low in fiber - contributes to obesity and inflammation worldwide. There is evidence in animals that these signs of inflammation are reversible within 4 weeks when changed to a more balanced diet. Thus, this study aims to assess whether there are detectable decreases in inflammation of the skin and body of psoriasis patients who usually eat a Western Diet on an EXPLORER PET scan following 6 weeks of a more balanced diet.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults (>18 year)
Both sexes
Must have a history of psoriasis of at least 3% body surface area affected by skin psoriasis (in a body area that the subject will allow the PI to perform several skin biopsies as noted below (optional)) and may carry a diagnosis of psoriatic arthritis as well
Patients will have a BMI of >/=25 which is consistent with being overweight - Willing and able to fast for at least 6 hours before and for the duration of the scan visit
Disqualifiers
Those taking anti-diabetic oral or injected medications
Those already ingesting a caloric- or component-restricted diet
Vegan, vegetarian or food allergy or intolerance to the ingredients of the diet
>5% change in body weight in the last 2 months
Trial design
Single group
Treatments tested in this trial
Dietary Counseling
BehavioralA Registered Dietitian or Nutritionist will provide nutrition education either in person, over the phone, or via Zoom. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant.
Treatment groups
Trial outcomes
Primary outcomes
Inflammation in PET/CT scan
measuring inflammation in PET imaging by calculating the maximum standardized uptake values (SUVmax) in given areas of interest (e.g., joint, blood vessel)
Secondary outcomes
Microbiomes Diversity
Measuring changes in stool and skin microbiome both through alpha diversity analysis measured in operational taxonomic units, and through beta diversity analysis using unweighted UniFrac Distance Principal Coordinates Analysis Plots (Shi et al.,2021)
Serum Inflammatory Markers
measuring TNF, IL-17A, and CRP levels through ELISA methods in blood samples
Cell Surface Inflammatory Markers
measuring cell surface integrin, L-selectin, CD11b, and CD66b levels by standard flow cytometric methods in blood samples.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.